AVE Science & Technology Co

AVE Science & Technology Co CapEx/D&A

The CapEx to Depreciation Ratio of AVE Science & Technology Co (688067.SS) as of Nov 4, 2026 is 0.50. In the previous year, CapEx to Depreciation Ratio was 0.67 — a change of -25.49% (lower).

CapEx/D&A

0.50

YoY

-25.49%

Last updated:

CapEx to Depreciation Ratio of AVE Science & Technology Co is 2024 0.50 . CapEx to Depreciation Ratio of AVE Science & Technology Co was 2023 0.67 . It decreases by -25.49% lower compared to the previous year.

The AVE Science & Technology Co CapEx/D&A history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/D&A
Date
CapEx/D&A
Jan 1, 2018
7.90 CNY
Jan 1, 2019
10.20 CNY
Jan 1, 2020
3.93 CNY
Jan 1, 2021
6.41 CNY
Jan 1, 2022
4.47 CNY
Jan 1, 2023
0.67 CNY
Jan 1, 2024
0.50 CNY
The AVE Science & Technology Co CapEx/D&A history
YEARCapEx/D&AYoY
0.50-25.49%
0.67-84.91%
4.47-30.28%
6.41+62.94%
3.93-61.44%
10.20+29.22%
7.90—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AVE Science & Technology Co Stock analysis

What does AVE Science & Technology Co do? AVE Science & Technology Co., Ltd. generates revenue through the research, development, production, sale, and service of clinical testing and analysis instruments. Its main products include urine formed component analyzer, urine dry chemistry analyzer, urine full item automatic analyzer, automatic stool analyzer, automatic body fluid analyzer, reproductive tract secretion analyzer, and special supporting in vitro diagnostic reagents and medical consumables. These products are primarily sold to inspection departments within medical and health institutions in both domestic and overseas markets. The company serves healthcare facilities that require diagnostic equipment for laboratory testing and patient care. The firm's product portfolio targets healthcare institutions seeking advanced diagnostic tools for efficient clinical analysis. By focusing on specialized instruments like urine and stool analyzers, AVE Science & Technology addresses specific needs in medical testing departments. The company's domestic and international distribution channels ensure broad market access for its diagnostic solutions. AVE Science & Technology's revenue streams are derived from the sale of its comprehensive range of clinical testing instruments and related consumables. The company's domestic market presence and overseas sales contribute to its overall business performance. Its products support routine diagnostic procedures across various healthcare settings, driving consistent demand for its equipment and reagents. AVE Science & Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AVE Science & Technology Co stock

CapEx to Depreciation Ratio of AVE Science & Technology Co is 0.50 in 2024.

CapEx to Depreciation Ratio of AVE Science & Technology Co changed from 0.67 to 0.50, representing a -25.49% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Depreciation Ratio AVE Science & Technology Co since 2006 – with annual values, charts, and detailed analysis.

The CapEx/D&A ratio compares investment spending to asset depreciation. Ratios above 1.0x indicate the company is growing its asset base, below 1.0x suggests underinvestment.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Depreciation Ratio's AVE Science & Technology Co with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Depreciation Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Depreciation Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — AVE Science & Technology Co

All Key Metrics — AVE Science & Technology Co